What changed
$CVS — Operates pharmacies and provides health insurance services.
🎯 Q1 FY26 | Rev $100B | EPS $2.57 vs $2.21 🟢 | Margin 4.7%
💡 Consensus expected Q1 2026 EPS of $2.21, but CVS delivered $2.57 — a 16.5% beat — and raised full-year guidance. The market is still pricing in skepticism about managed care margins and retail headwinds, but the beat was driven by strong Health Services (PBM) performance and cost control.
🏢 Business Quality: 7/10 | Valuation: cheap
📉 Reward/Risk: Upside 15% to $113 (13x FY26 EPS of $7.43 + 10% beat) vs downside 10% to $88 (if guidance cut). Ratio: 1.5:1.
🔮 Catalyst: Q2 2026 earnings (early Aug 2026). Watch: Adjusted EPS vs consensus $1.71, and full-year guidance update. Failure signal: if Q2 EPS misses or guidance is cut.
💰 Entry: Current price $98.02 is attractive. Ideal entry below $95, but the post-earnings momentum suggests limited downside.
Also in play: $WBA $RAD $MCK $ABC $CAH $NVS